+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dermatitis Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery

  • ID: 4852471
  • Report
  • September 2020
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AbbVie Inc.
  • Bayer HealthCare
  • Connetics Corporation
  • Fujisawa Healthcare
  • Meda Pharmaceuticals
  • Novartis AG
  • MORE
Dermatitis Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global dermatitis drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the dermatitis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? the Dermatitis Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) by Drug Class: Corticosteroids; Emollients/Moisturizers; Antihistamines; Calcineurin Inhibitors; Antibiotics; Immunomodulators; Interleukin Inhibitors
2) by Distribution Channel: Hospital; Retail Pharmacies; Drug Stores; Online Or Mail Pharmacies
3) by Route of Application: Topical; Oral; Injectable
4) by Application: Cancer; Blood Disorders; Chronic Diseases; Infectious Diseases

Companies Mentioned: LEO Pharma A/S; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi S.A.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Bayer HealthCare
  • Connetics Corporation
  • Fujisawa Healthcare
  • Meda Pharmaceuticals
  • Novartis AG
  • MORE
1. Executive Summary

2. Dermatitis Drugs Market Characteristics

3. Dermatitis Drugs Market Size And Growth
3.1. Global Dermatitis Drugs Historic Market, 2015-2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Dermatitis Drugs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Dermatitis Drugs Market Segmentation
4.1. Global Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Corticosteroids
  • Emollients/Moisturizers
  • Antihistamines
  • Calcineurin Inhibitors
  • Antibiotics
  • Immunomodulators
  • Interleukin Inhibitors
4.2. Global Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospital
  • Retail Pharmacies
  • Drug Stores
  • Online Or Mail Pharmacies
4.3. Global Dermatitis Drugs Market, Segmentation By Route Of Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Topical
  • Oral
  • Injectable
4.4. Global Dermatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Cancer
  • Blood Disorders
  • Chronic Diseases
  • Infectious Diseases
5. Dermatitis Drugs Market Regional And Country Analysis
5.1. Global Dermatitis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Dermatitis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Dermatitis Drugs Market
6.1. Asia-Pacific Dermatitis Drugs Market Overview
6.2. Asia-Pacific Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Dermatitis Drugs Market
7.1. China Dermatitis Drugs Market Overview
7.2. China Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Dermatitis Drugs Market
8.1. India Dermatitis Drugs Market Overview
8.2. India Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Dermatitis Drugs Market
9.1. Japan Dermatitis Drugs Market Overview
9.2. Japan Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Dermatitis Drugs Market
10.1. Australia Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Dermatitis Drugs Market
11.1. Indonesia Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Dermatitis Drugs Market
12.1. South Korea Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Dermatitis Drugs Market
13.1. Western Europe Dermatitis Drugs Market Overview
13.2. Western Europe Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Dermatitis Drugs Market
14.1. UK Dermatitis Drugs Market Overview
14.2. UK Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Dermatitis Drugs Market
15.1. Germany Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Dermatitis Drugs Market
16.4. France Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Dermatitis Drugs Market
17.1. Eastern Europe Dermatitis Drugs Market Overview
17.2. Eastern Europe Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Dermatitis Drugs Market
18.1. Russia Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Dermatitis Drugs Market
19.1. North America Dermatitis Drugs Market Overview
19.2. North America Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Dermatitis Drugs Market
20.1. USA Dermatitis Drugs Market Overview
20.2. USA Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Dermatitis Drugs Market
21.1. South America Dermatitis Drugs Market Overview
21.2. South America Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Dermatitis Drugs Market
22.1. Brazil Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Dermatitis Drugs Market
23.1. Middle East Dermatitis Drugs Market Overview
23.2. Middle East Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Dermatitis Drugs Market
24.1. Africa Dermatitis Drugs Market Overview
24.2. Africa Dermatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Dermatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Dermatitis Drugs Market Competitive Landscape And Company Profiles
25.1. Dermatitis Drugs Market Competitive Landscape
25.2. Dermatitis Drugs Market Company Profiles
25.2.1. LEO Pharma A/S
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Novartis AG
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Pfizer Inc.
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Regeneron Pharmaceuticals Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Sanofi S.A.
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Dermatitis Drugs Market

27. Dermatitis Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Dermatitis Drugs Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. About the Publisher
30.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Bayer HealthCare
  • Connetics Corporation
  • Fujisawa Healthcare
  • Meda Pharmaceuticals
  • Novartis AG
  • MORE
Major players in the dermatitis drugs market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc. and Sanofi S.A.

The global dermatitis drugs market is expected to decline from $5.4 billion in 2019 to $4.7 billion in 2020 at a compound annual growth rate (CAGR) of -13.9%. The decline is mainly because of drop in sales due to the lockdown measures to contain COVID-19 spread. Apart from restricting non-emergency medical services, new rules of the governments across the globe has forced many companies in the dermatology drug market to halt their business operations which has impacted the market growth. The market is then expected to recover and grow at a CAGR of 5.7% from 2021 and reach $7.1 billion in 2023.

The dermatitis drugs market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex.

North America was the largest region in the dermatitis drugs market. The dermatitis drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) that carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes makes the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market.

The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). In order to find the efficacy and efficiency of drug, it has to be tried on the every type of patients. The effects of certain drugs in adults are quite different than in children, as a reason results of the clinical trial cannot be used for the production of drug that will be served to the children. This hinders the research and requires more efforts in clearing regulation set by FDA. For example, as the patient population is largely children, FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation is in compliance with Children’s Health Act of 2000 that requires all the children subjected to clinical trial be given additional protection.

The Dermatitis market has witnessed a trend of increasing Mergers and Acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business. For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also Biofrontera, Inc., a specialist in dermatology market acquired Cutanea Life Sciences, Inc.in 2019 for $7.3 million to increase their capital base and scale the business.

Growth in Atopic Dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, a study conducted in Norway highlights that the overall incidence rate of atopic dermatitis has increased from 0.028 per person year in 2009 to 0.034 per person year in 2014.
Note: Product cover images may vary from those shown
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Bayer HealthCare
  • Encore Dermatology Inc.
  • Meda Pharmaceuticals
  • Allergan Plc. (Republic of Ireland)
  • Bristol-Myers Squibb
  • Anacor Pharmaceutical Inc.
  • Astellas Pharma Inc.
  • Mylan
  • Valeant Pharmaceutical Inc.
  • Galderma SA
  • Dow Pharm
  • Connetics Corporation
  • Fujisawa Healthcare
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Velite Pharmaceutical
  • GlaxoSmithKline plc.
  • Medimmune (Astrazeneca)
  • Bausch Health
  • Nestlé Skin Health (Galderma)
  • Medimmune (Astrazeneca)
  • Aqua Pharmaceuticals
  • Boehringer Ingelheim
  • Biofrontera AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll